Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

SC.20 (A Phase III International Randomized Trial of Single versus Multiple Fractions for Re-Irradiation of Painful Bone Metastases) and its companion study SC.20U (Study of the Effect of Re-Irradiation for Bone Pain on Urinary Markers of Osteoclast Activity) reached the target accrual of 850 patients for the main study today. Both studies are closed to accrual effective immediately.

All patients are expected to complete protocol treatment within 6 weeks.

Canadian Cancer Trials Group SC.20 was an international collaboration led by Canadian Cancer Trials Group with contributions from groups in the US, Europe and Australia.

Congratulations and thanks to all participating centres, staff and patients for helping to ensure the success of this trial.